Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback